JW Life Sciences

What JW Life Sciences does

JW Life Sciences Co., Ltd. is a South Korea-based pharmaceutical manufacturer specializing in intravenous (IV) infusion solutions, with operations centered on a single integrated Dangjin Production Complex and a corporate R&D headquarters in Gwacheon. Founded in 1994 (originally as Choongwae Chemical Corp.) and listed on KOSPI since 2016, the company is a subsidiary of JW Holdings and serves three customer segments: Korean pharmaceutical companies and hospital groups via domestic CMO/CDMO services, global pharmaceutical partners via EU GMP-certified contract manufacturing, and overseas distributors in 23+ countries across Europe, Asia, Oceania, and Africa. The company holds approximately 40% domestic market share in Korea's IV solutions market.

The company's product portfolio spans Basic IV fluids (Normal Saline, 5% Dextrose), Total Parenteral Nutrition (TPN) products (Winuf / Finomel, including 3-chamber systems), Specialty IV solutions (antibiotics, renal therapies), and amino acid solutions (Combiflex, Freamine, Glutasol). Underlying technology is built on proprietary Non-PVC container materials (US FDA-approved 2003, China SFDA 2004), 3-chamber TPN systems (Asia's first, designated Korean Government World-Class Product in 2019), lipid emulsion technology including MCT and omega-3 formulations, Form-Fill-Seal automated manufacturing, and a 13-step sterile injection manufacturing process. Manufacturing capacity includes the world's largest eco-friendly Non-PVC IV plant and the largest CAPA in Korea for both basic IV (14M units/year, expanded to 119M units/year in 2022) and TPN (12.2M units/year). Regulatory certifications include EU GMP (2018, Asia's first for TPN), US FDA, China SFDA, ISO 14001, ISO 37001, and ISO 37301.

Revenue is generated primarily through three streams: domestic CMO/CDMO contract manufacturing, domestic product sales via JW Pharmaceutical's distribution network, and global CDMO/export including exclusive supply to Baxter International for 3rd generation TPN products (Winuf/Finomel) and a 2020 exclusive technology license to Shandong Luoxin for the Chinese market. FY2024 consolidated revenue was KRW 222.478 billion (~USD 166M), with operating income of KRW 35.858 billion (16.1% margin) and net income of KRW 43.988 billion, reflecting steady top-line growth and significant profitability improvement from KRW 12.9B net income in 2021.

Name

JW Life Sciences

Legal name

JW Life Science Co., Ltd.

Website

https://jw-lifescience.co.kr

Company type

Public

Founded year

1994

Operating status

Operating

Short description

JW Life Sciences is a South Korea-based pharmaceutical manufacturer of IV infusion solutions and Total Parenteral Nutrition (TPN) products, serving Korean hospitals and pharma companies via domestic CMO/CDMO services and exporting to 23+ countries through partners including Baxter International.

Ownership category

akta.pro rank

Product category

Intravenous Infusion Solutions

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)

akta.pro secondary industries

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

Keywords

• Intravenous infusion solutions
• Parenteral nutrition products
• Pharmaceutical contract manufacturing
• Non-PVC IV containers
• Sterile injectable manufacturing

Headquarters

HQ city

Yangjin

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Domestic CMO/CDMO Manufacturing: Contract manufacturing services for domestic pharmaceutical companies, hospital groups, and healthcare enterprises. Produces basic IV solutions, specialty IV solutions, and TPN products.
2. Global CDMO/Export: Export of IV solution products to international markets including Europe (13 countries), Asia (7 countries), Oceania, and Africa (2 countries). EU-GMP certified manufacturing for global pharmaceutical partners including Baxter International.
3. Product Sales (Domestic): Direct sales of IV solutions including Winuf (TPN), basic IV fluids (5% dextrose, normal saline), and specialty IV products. Market leader with approximately 40% domestic market share.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

JW Life Sciences develops and manufactures intravenous (IV) infusion solutions for the pharmaceutical and healthcare industries, spanning basic IV fluids (5% Dextrose, Normal Saline), specialty IV solutions (antibiotics), amino acid injections, and Total Parenteral Nutrition (TPN) products in 3-chamber containers. The company also operates as a B2B CDMO/CMO, providing contract manufacturing, regulatory support, and technology licensing to domestic and global pharmaceutical partners under EU-GMP, US FDA, and China SFDA certifications. Products are supplied domestically through JW Pharmaceutical's distribution network and exported globally to 23+ countries, including exclusive partnerships with Baxter International for flagship TPN brands Winuf and Finomel.

Product overview

JW Life Sciences is a pharmaceutical company specializing in IV (intravenous) infusion solutions, operating as part of the JW Holdings group. The company offers a comprehensive portfolio covering the full spectrum of IV infusion products including Basic IV solutions (Normal Saline, Dextrose), Total Parenteral Nutrition (TPN) products (위너프/Winuf, 피노멜/Finomel), Specialty IV solutions (antibiotics, renal therapies), and amino acid solutions (Combiflex, Freamine, Glutasol). Products are delivered through various container systems including Non-PVC multi-chamber bags (2CB, 3CB), PP bottles, and PE bottles. The company operates manufacturing facilities in Dangjin, Chungnam with annual production capacity of 119 million basic IV units and 12.2 million TPN units, serving both domestic (approx. 40% market share) and international markets including Europe, Asia, Oceania, and Africa.

Differentiator

Problem solved

Functional benefit

Products and services

• Winuf (위너프) 3-Chamber TPN 3-Chamber Total Parenteral Nutrition (TPN) product containing glucose, amino acids, and lipids in separate compartments that mix just before use. No.1 domestic market share in Korea for TPN; first Asian TPN exported to Europe (EU) and supplied to Baxter International under exclusive supply agreement.
• Finomel (피노멜) 3rd generation 3-chamber TPN nutrient solution. Asia's first product to receive EU product approval for this category; exported to 13 European countries including Germany, UK, and France.
• Combiflex Lipid Central Inj. Amino acids and TPN product for central infusion containing lipid emulsion for complete nutritional support.
• Combiflex Lipid Peri Inj. Peripheral-compatible 3-chamber amino acid and lipid TPN product for patients who cannot receive central venous nutrition.
• Combiflex Lipid Inj Combined lipid-based TPN solution containing amino acids and lipids for comprehensive patient nutrition.
• Combiflex Inj 2-chamber system (2CB) amino acid solution developed first in Korea, allowing mixing of glucose and amino acid chambers before administration.
• Combiflex MCT Peri Inj. 3-chamber (3CB) medium-chain triglyceride based amino acid solution for peripheral administration.
• Freamine 10% Inj 10% concentration amino acid injection solution for parenteral nutrition support.
• Freamine 8.5% Inj 8.5% concentration amino acid injection solution for parenteral nutrition.
• Glutasol Inj Amino acid solution for nutritional support, containing glutamine and other amino acids.
• Cletamin Inj Amino acid and TPN product for specialized nutritional therapy.
• Choongwae Ciprofloxacin Inj Antibiotic injection solution for treating bacterial infections, classified as a specialty IV solution.
• Normal Saline (생리식염수) Basic IV fluid (0.9% sodium chloride solution) for fluid and electrolyte replacement. Government-designated essential medicine with widest hospital supply in Korea.
• 5% Dextrose (5% 포도당) Basic IV fluid providing glucose calories and hydration. Government-designated essential medicine widely supplied to hospitals.
• CDMO/CMO Contract Manufacturing Services B2B contract development and manufacturing services for domestic and global pharmaceutical companies, hospital groups, and healthcare enterprises. Produces basic IV solutions, specialty IV solutions, and TPN products with EU-GMP, US FDA cGMP, and China SFDA certified quality systems; includes regulatory support for overseas approvals (CTD preparation, inspection readiness).
• Winuf Technology Licensing for China Market Exclusive technology export and supply agreement licensing JW's Winuf TPN technology to Shandong Luoxin Pharmaceutical Group for local production and distribution in China.

Quantifiable outcome

• 40% domestic IV market share
• +3 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered core.

• Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. (China)coreStrategic or Co-development Partner · 1 January 2020Winuf exclusive technology export and supply agreement signed in 2020. JW Life Sciences licensed its TPN technology to the Chinese pharmaceutical company for local production and distribution in China.
• Baxter InternationalcoreStrategic or Co-development Partner · 1 January 2013Exclusive supply agreement signed in 2013 for 3rd generation TPN products. JW Life Sciences supplies Winuf/Finomel products to Baxter for global distribution. This partnership enabled JW to become the first Asian company to export TPN products to Europe.
• JW Chemi TowncoreTechnology or IntegrationSubsidiary of JW Holdings providing film/material technology for Non-PVC IV container manufacturing. Supplies proprietary film materials for JW Life Sciences' eco-friendly container production.
• JW Pharmaceutical (JW중외제약)coreChannel Partner/ Reseller/ DistributorJW Group company providing distribution services for JW Life Sciences' domestic IV products. Leverages Korea's No.1 pharmaceutical distribution network for hospital supply.
• JW HoldingscoreOthersParent holding company providing strategic direction, governance, and coordination across JW Group pharmaceutical subsidiaries including JW Life Sciences.

Scale indicators11 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Sichuan Kelun Pharmaceutical: Sichuan Kelun is one of China's largest IV solution manufacturers with a comprehensive infusion portfolio including TPN, basic IV, and specialty products. It is a direct competitive peer in the Asian IV market, sharing product range and CDMO positioning with JW Life Sciences.
• Fresenius Kabi: Fresenius Kabi is one of the world's largest IV infusion and clinical nutrition manufacturers, with a global portfolio of basic IV solutions, TPN (SmofKabiven/Kabiven), lipid emulsions, and amino acids. It is the closest pure-play peer to JW Life Sciences across product categories, regulatory footprint, and CDMO-style manufacturing capabilities.
• ICU Medical: ICU Medical manufactures IV solutions, infusion sets, and closed-system transfer devices, and acquired Pfizer's Hospira Infusion Systems business. It is a direct comparable in sterile IV manufacturing, IV containers, and global distribution channels serving hospital pharmacy customers.
• B. Braun: B. Braun is a major German medical and pharmaceutical company with a substantial IV solutions, infusion pumps, and clinical nutrition portfolio. It competes head-to-head with JW in European TPN markets and shares similar dual-play positioning across basic IV, specialty IV, and sterile manufacturing services.
• Baxter International: Baxter is a global IV solutions and clinical nutrition leader (Viaflex, Clinimix, Clinolipid) and JW Life Sciences' exclusive distribution partner for TPN. Despite the partnership, Baxter competes directly with JW in many international markets and serves as both the benchmark and largest single customer for JW's premium TPN products.

Others

• JW Pharmaceutical: JW Pharmaceutical is the sister company under JW Holdings and serves as JW Life Sciences' primary domestic distribution partner. While not a direct competitor, it shares the JW Group umbrella, customer base, and brand, making it a structural peer for understanding the Korean pharmaceutical market context.
• JW Bioscience: JW Bioscience is another JW Holdings affiliate that was acquired by JW Life Sciences in 2020 as part of business restructuring. It is adjacent within the group ecosystem rather than a direct competitor, but relevant for understanding JW Life Sciences' broader Korean pharmaceutical positioning.

Broad incumbents

• Terumo Corporation: Terumo is a Japanese medical device and pharmaceutical company with a meaningful IV solutions and infusion systems business across Asia. Its regional Asian scale, hospital channel presence, and broader portfolio make it a comparable incumbent peer, particularly for JW's Asian expansion ambitions.
• Otsuka Pharmaceutical: Otsuka operates a pharmaceutical business with IV infusion products (including clinical nutrition) across Asia and global markets. It competes in the same hospital pharmacy channels and is relevant as a broader Japanese pharma incumbent with overlapping IV and clinical nutrition capabilities.

Emerging players

• Grifols: Grifols produces clinical nutrition products (parenteral and enteral) alongside its core plasma business. While smaller than Fresenius Kabi or Baxter in IV, its TPN/amino acid portfolio and global hospital channel make it a relevant peer for product overlap and competitive benchmarking.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about JW Life Sciences